OTCM
BJTRF
Market cap604mUSD
, Last price
Name
Beijing Tong Ren Tang Chinese Medicine Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Beijing Tong Ren Tang Chinese Medicine Company Limited (BJTRF) is an entity primarily engaged in the manufacturing, retailing, and wholesale distribution of traditional Chinese medicine and various healthcare products, catering to both bulk purchasers and individual consumers. The company further provides traditional Chinese medical consultation and treatment services. Its operational scope is divided across three key regions: Hong Kong, Mainland China, and other international markets. With a substantial retail presence, it manages 23 outlets in Hong Kong and an additional 46 stores distributed across Asia, Oceania, North America, and Europe. All its merchandise is marketed under the well-known Tong Ren Tang brand. This historic firm, established in 1669, maintains its corporate headquarters in Wan Chai, Hong Kong.
Key people
Han Yan
Executive Chairman of the Board · since 2025
Fung Yi Tsang
Chief Financial Officer, Company Secretary · since 2020
Zheng Guo Shen
General Counsel, Deputy General Manager · since 2022
Wei Wu
Deputy General Manager · since 2020
Jiliang Zhang
Deputy General Manager · since 2022
Chi Wang
Chief Executive Officer, Executive Director · since 2024
Li Feng
Non-Executive Director · since 2023
Non-Executive Independent Director · since 2013
Independent Non-Executive Director · since 2017
Non-Executive Independent Director · since 2023
Valuation
Title HKD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||